Evidence map›Paper›PMID 33922073›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Terbium-Based AGuIX-Design Nanoparticle to Mediate X-ray-Induced Photodynamic Therapy.

Joël Daouk, Mathilde Iltis, Batoul Dhaini, Denise Béchet, Philippe Arnoux, Paul Rocchi, Alain Delconte, Benoît Habermeyer, François Lux, Céline Frochot and 3 more

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joël DaoukDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.ORCID 0000-0001-8042-1726
Mathilde IltisDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.
Batoul DhainiReactions and Chemical Engineering Laboratory (LRGP), UMR 7274, Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.ORCID 0000-0003-0372-2159
Denise BéchetDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.
Philippe ArnouxReactions and Chemical Engineering Laboratory (LRGP), UMR 7274, Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.ORCID 0000-0002-6834-9597
Paul RocchiLight Matter Institute, UMR-5306, Université de Lyon-French National Scientific Research Center (CNRS), F-69000 Lyon, France.
Alain DelconteDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.
Benoît HabermeyerPorphychem SAS, F-21000 Dijon, France.
François LuxLight Matter Institute, UMR-5306, Université de Lyon-French National Scientific Research Center (CNRS), F-69000 Lyon, France.
Céline FrochotReactions and Chemical Engineering Laboratory (LRGP), UMR 7274, Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.ORCID 0000-0002-7659-3864
Olivier TillementLight Matter Institute, UMR-5306, Université de Lyon-French National Scientific Research Center (CNRS), F-69000 Lyon, France.
Muriel Barberi-HeyobDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.
Hervé SchohnDepartment of Biology, Signals and Systems in Cancer and Neuroscience, UMR 7039 Research Center for Automatic Control (CRAN), Université de Lorraine-French National Scientific Research Center (CNRS), F-54000 Nancy, France.ORCID 0000-0002-3651-2636

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-ray-induced photodynamic therapy is based on the energy transfer from a nanoscintillator to a photosensitizer molecule, whose activation leads to singlet oxygen and radical species generation, triggering cancer cells to cell death. Herein, we synthesized ultra-small nanoparticle chelated with Terbium (Tb) as a nanoscintillator and 5-(4-carboxyphenyl succinimide ester)-10,15,20-triphenyl porphyrin (P1) as a photosensitizer (AGuIX@Tb-P1). The synthesis was based on the AGuIX@ platform design. AGuIX@Tb-P1 was characterised for its photo-physical and physico-chemical properties. The effect of the nanoparticles was studied using human glioblastoma U-251 MG cells and was compared to treatment with AGuIX@ nanoparticles doped with Gadolinium (Gd) and P1 (AguIX@Gd-P1). We demonstrated that the AGuIX@Tb-P1 design was consistent with X-ray photon energy transfer from Terbium to P1. Both nanoparticles had similar dark cytotoxicity and they were absorbed in a similar rate within the cells. Pre-treated cells exposure to X-rays was related to reactive species production. Using clonogenic assays, establishment of survival curves allowed discrimination of the impact of radiation treatment from X-ray-induced photodynamic effect. We showed that cell growth arrest was increased (35%-increase) when cells were treated with AGuIX@Tb-P1 compared to the nanoparticle doped with Gd.

Indexed as

AGuIX®, terbiumgadoliniumglioblastoma multiformephotodynamic therapysinglet oxygenX-ray-induced photodynamic therapy

Identifiers

PMID33922073
PMCPMC8143523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.